Dishman Carbogen Amcis Ltd, a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies, has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year, an increase of 13.8%

 

EBITDA stood at Rs. 114.87 crore for Q3 FY23 as compared to Rs. 109.5 crore during the corresponding period of previous year, an increase of 4.9%. 

 

EBITDA Margin at 18% for Q3 FY23 as against 19.5% in Q3 FY22 whereas Net Profit of Rs. 46.96 crore for Q3 FY23 as compared to Rs. 35.38 crore in the corresponding period of the previous year, an increase of 32.7%. 

 

Net profit of Rs. 46.96 crore for Q3 FY23 as compared to Rs. 35.38 crore in the corresponding period of the previous year, an increase of 32.7%.